{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:56:25Z","timestamp":1788292585601,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genomedia"},{"name":"Guardant Health AMEA"},{"DOI":"10.13039\/100031949","name":"Guardant Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031949","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tempus Labs"},{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers Squibb"},{"name":"Eisai"},{"name":"FALCO biosystems"},{"DOI":"10.13039\/100032770","name":"Medical & Biological Laboratories","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032770","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merus N.V."},{"name":"Molecular Health GmbH"},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Nippon Boehringer Ingelheim","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017981","name":"Sysmex Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017981","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01154-7","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:14:23Z","timestamp":1763482463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genomic alteration and clinical significance of circulating tumor DNA in patients with advanced urothelial cancer: SCRUM-Japan monstar screen project"],"prefix":"10.1038","volume":"9","author":[{"given":"Takahiro","family":"Osawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taigo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashige","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yota","family":"Yasumizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Abutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smruthy","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1154_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal, R., Valderrama, B. P. & Bellmunt, J. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat. Rev. Clin. Oncol. 21, 8\u201327 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1154_CR2","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/cas.16097","volume":"115","author":"Y Bao","year":"2024","unstructured":"Bao, Y., Zhang, D., Guo, H. & Ma, W. Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Sci. 115, 1060\u20131072 (2024).","journal-title":"Cancer Sci."},{"key":"1154_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","volume":"25","author":"AR Parikh","year":"2019","unstructured":"Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat. Med. 25, 1415\u20131421 (2019).","journal-title":"Nat. Med."},{"key":"1154_CR4","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen, E. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 1547\u20131557 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1154_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432\u2013437 (2021).","journal-title":"Nature"},{"key":"1154_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20493-6","volume":"12","author":"G Vandekerkhove","year":"2021","unstructured":"Vandekerkhove, G. et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat. Commun. 12, 184 (2021).","journal-title":"Nat. Commun."},{"key":"1154_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.euo.2019.08.004","volume":"4","author":"HJ Chalfin","year":"2021","unstructured":"Chalfin, H. J. et al. Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer. Eur. Urol. Oncol. 4, 310\u2013314 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1154_CR8","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.euo.2019.02.004","volume":"3","author":"P Grivas","year":"2020","unstructured":"Grivas, P. et al. Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study. Eur. Urol. Oncol. 3, 695\u2013699 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"1154_CR9","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","volume":"23","author":"G Vandekerkhove","year":"2017","unstructured":"Vandekerkhove, G. et al. Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clin. Cancer Res. 23, 6487\u20136497 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1154_CR10","doi-asserted-by":"publisher","first-page":"e910","DOI":"10.1093\/oncolo\/oyad120","volume":"28","author":"T Peak","year":"2023","unstructured":"Peak, T. et al. Comparative genomic landscape of urothelial carcinoma of the bladder among patients of east and south asian genomic ancestry. Oncologist 28, e910\u2013e920 (2023).","journal-title":"Oncologist"},{"key":"1154_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.21.02286","volume":"40","author":"CJ Gibson","year":"2022","unstructured":"Gibson, C. J. et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J. Clin. Oncol. 40, 189\u2013201 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1154_CR12","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1158\/0008-5472.CAN-22-0985","volume":"82","author":"CH Marshall","year":"2022","unstructured":"Marshall, C. H., Gondek, L. P., Luo, J. & Antonarakis, E. S. Clonal hematopoiesis of indeterminate potential in patients with solid tumor malignancies. Cancer Res. 82, 4107\u20134113 (2022).","journal-title":"Cancer Res."},{"key":"1154_CR13","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1016\/j.annonc.2023.09.2867","volume":"34","author":"Y Belkouchi","year":"2023","unstructured":"Belkouchi, Y. et al. 142P Correlating total tumor volume on CT-Scan and liquid biopsy ctDNA in 1017 patients with metastatic cancer: a novel study. Ann. Oncol. 34, S237 (2023).","journal-title":"Ann. Oncol."},{"key":"1154_CR14","doi-asserted-by":"publisher","first-page":"e2100535","DOI":"10.1200\/PO.21.00535","volume":"6","author":"H Bando","year":"2022","unstructured":"Bando, H. et al. Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer. JCO Precis. Oncol. 6, e2100535 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"1154_CR15","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca, N. M. et al. Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat. Commun. 15, 1828 (2024).","journal-title":"Nat. Commun."},{"key":"1154_CR16","unstructured":"Huang, M. et al. (American Society of Clinical Oncology, 2024)."},{"key":"1154_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","volume":"39","author":"Y Fujii","year":"2021","unstructured":"Fujii, Y. et al. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell 39, 793\u2013809 (2021).","journal-title":"Cancer Cell"},{"key":"1154_CR18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","volume":"68","author":"JP Sfakianos","year":"2015","unstructured":"Sfakianos, J. P. et al. Genomic characterization of upper tract urothelial carcinoma. Eur. Urol. 68, 970\u2013977 (2015).","journal-title":"Eur. Urol."},{"key":"1154_CR19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.euo.2020.12.007","volume":"4","author":"JP Sfakianos","year":"2021","unstructured":"Sfakianos, J. P. et al. Genetic differences between bladder and upper urinary tract carcinoma: implications for therapy. Eur. Urol. Oncol. 4, 170\u2013179 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1154_CR20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-14-2662","volume":"21","author":"F McCormick","year":"2015","unstructured":"McCormick, F. KRAS as a therapeutic target. Clin. Cancer Res. 21, 1797\u20131801 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1154_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","volume":"25","author":"F Audenet","year":"2019","unstructured":"Audenet, F. et al. Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin. Cancer Res. 25, 967\u2013976 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1154_CR22","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/cncr.31314","volume":"124","author":"N Agarwal","year":"2018","unstructured":"Agarwal, N. et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer 124, 2115\u20132124 (2018).","journal-title":"Cancer"},{"key":"1154_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.eururo.2020.05.039","volume":"78","author":"MR Hassler","year":"2020","unstructured":"Hassler, M. R. et al. Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature. Eur. Urol. 78, 209\u2013220 (2020).","journal-title":"Eur. Urol."},{"key":"1154_CR24","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson, B. D. et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat. Commun. 10, 2977 (2019).","journal-title":"Nat. Commun."},{"key":"1154_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41417-020-0174-y","volume":"27","author":"K Choucair","year":"2020","unstructured":"Choucair, K. et al. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther. 27, 841\u2013853 (2020).","journal-title":"Cancer Gene Ther."},{"key":"1154_CR26","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1154_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","volume":"34","author":"ZR Reichert","year":"2023","unstructured":"Reichert, Z. R. et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO 34, 111\u2013120 (2023).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO"},{"key":"1154_CR28","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.euf.2022.04.017","volume":"8","author":"E Laukhtina","year":"2022","unstructured":"Laukhtina, E. et al. Circulating tumour DNA is a strong predictor of outcomes in patients treated with systemic therapy for urothelial carcinoma. Eur. Urol. Focus 8, 1683\u20131686 (2022).","journal-title":"Eur. Urol. Focus"},{"key":"1154_CR29","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.esmorw.2023.100004","volume":"3","author":"B Miron","year":"2024","unstructured":"Miron, B. et al. Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer. ESMO Real. World Data Digit. Oncol. 3, 100004 (2024).","journal-title":"ESMO Real. World Data Digit. Oncol."},{"key":"1154_CR30","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/ijc.29526","volume":"137","author":"I Hosen","year":"2015","unstructured":"Hosen, I. et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int. J. cancer 137, 1621\u20131629 (2015).","journal-title":"Int. J. cancer"},{"key":"1154_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-023-01349-9","volume":"23","author":"H Shuai","year":"2023","unstructured":"Shuai, H., Duan, X., Zhou, J.-J., Liu, Y. & Wu, T. Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis. BMC Urol. 23, 177 (2023).","journal-title":"BMC Urol."},{"key":"1154_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/1541-7786.MCR-20-0751","volume":"19","author":"O Alhalabi","year":"2021","unstructured":"Alhalabi, O. et al. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol. Cancer Res. 19, 395\u2013402 (2021).","journal-title":"Mol. Cancer Res."},{"key":"1154_CR33","doi-asserted-by":"publisher","first-page":"e0237802","DOI":"10.1371\/journal.pone.0237802","volume":"15","author":"R Woodhouse","year":"2020","unstructured":"Woodhouse, R. et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One 15, e0237802 (2020).","journal-title":"PLoS One"},{"key":"1154_CR34","doi-asserted-by":"publisher","first-page":"100003","DOI":"10.1016\/j.jlb.2023.100003","volume":"1","author":"S Mishima","year":"2023","unstructured":"Mishima, S. et al. Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN. J. Liq. Biopsy 1, 100003 (2023).","journal-title":"J. Liq. Biopsy"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01154-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01154-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01154-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:07:20Z","timestamp":1763528840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01154-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01154-7","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial or non-financial interests, except as listed below: The authors declare the following potential conflicts of interest: Takao Fujisawa has received honoraria from Amelieff Co. Ltd. and AstraZeneca. Yoshiaki Nakamura has received honoraria from Guardant Health Pte Ltd., MSD K.K., Eisai Co., Ltd., Zeria Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., CareNet, Inc., Hisamitsu Pharmaceutical Co., Inc., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Becton, Dickinson and Company, and Guardant Health Japan Corp.; has served in consulting or advisory roles for Guardant Health Pte Ltd., Natera, Inc., Roche Ltd., Seagen, Inc., Premo Partners, Inc., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Exact Sciences Corporation, and Gilead Sciences, Inc.; and has received research funding from Seagen, Inc., Genomedia Inc., Guardant Health AMEA, Inc., Guardant Health, Inc., Tempus Labs, Inc., Roche Diagnostics K.K., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd. Takayuki Yoshino has received honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical, Merck Biopharma, Bayer Yakuhin, Ono Pharmaceutical, and MSD K.K.; has served in a consulting or advisory role for Sumitomo Corp.; and has received research funding from Amgen, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, FALCO biosystems, Genomedia, Medical & Biological Laboratories, Merus N.V., Molecular Health GmbH, MSD, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics, Sanofi, Sysmex, Taiho Pharmaceutical, and Takeda Pharmaceutical. Smruthy Sivakumar is an employee at Foundation Medicine, Inc. with an equity interest in Roche. Hikaru Abutani is an employee at Chugai Pharmaceutical Co., Ltd. Takaaki Oda is an employee at Chugai Pharmaceutical Co., Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}